The company's flagship product is the ProSense® Cryoablation System, described as a minimally invasive cryosurgical tool that uses liquid nitrogen to create large lethal zones for tumor destruction. The commercial-stage company markets its systems and technologies internationally, with presence in the United States, Japan, India, China, Israel, and other markets.
Cyborg Score Rationale
As of March 18, 2026, IceCure's stock price was $0.6001 with a market capitalization of approximately $50.3 million. The company received Nasdaq minimum bid price non-compliance notification in July 2024, requiring shares to maintain at least $1.00 per share. Limited revenue scale and capitalization constraints challenge growth execution.
Top Insights
Company raised $4.0 million in a registered direct offering in March 2026, selling 8 million ordinary shares at $0.50 per share to healthcare-focused institutional investors.
Beyond the lead ProSense single-probe system, the company developed a MultiSense multi-probe system expected to freeze several tumors simultaneously, which has not yet been commercialized.
IceCure was founded in 2006 as an Israel-based company developing cryoablation therapy.
The ProSense system has received FDA and CE approvals for market distribution.